Scientists from New York-Presbyterian Hospital have successfully tested an anti-palpitation nasal spray: The product could be a quick and easy way to relieve a tachycardia attack. The study was published on: Journal of the American Heart Association (JAHA).
Paroxysmal supraventricular tachycardia is a type of arrhythmia characterized by rapid (more than 100 beats per minute, more often 150-200 beats per minute) contraction of the lower chambers of the heart. Standard treatment during an attack involves performing vagal maneuvers (physical manipulation of the body to slow the transmission of signals along the vagus nerve). In 20-40% of cases, these techniques are ineffective and the patient must go to hospital.
169 patients participated in the new study. Of these, 105 self-administered at least one dose of etripamil (70 mg) nasal spray. The experiment lasted 232 days.
Etripamil spray normalized the heart rate within 30 minutes in 60.2% of tachycardia attacks and within one hour in 75.1%.
The drug was safe and well tolerated; 32.4% of participants reported one or more side effects of the medication; most commonly mild to moderate nasal congestion, discomfort, or runny nose. The drug is awaiting approval from the US Food and Drug Administration.
“Similar to the albuterol inhaler for patients with asthma or the epinephrine pen for patients with severe allergies or anaphylaxis, etripamil nasal spray may be an excellent option for people with paroxysmal supraventricular tachycardia,” the authors concluded.
Previous scientists to create Way to protect yourself from fatty liver.
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.